NCI E3805 (Scott), 2017 NCT00309985
docetaxel plus ADT (n=397) vs. androgen deprivation therapy (ADT) (n=393)
randomized controlled trial
metastatic, hormone-sensitive prostate cancer
STAMPEDE docetaxel, 2016 NCT00268476
docetaxel plus ADT (n=-9) vs. androgen deprivation therapy (ADT) (n=-9)
-
metastatic, hormone-sensitive prostate cancer
CHAARTED, 0 NCT00268476
docetaxel plus ADT (n=-9) vs. androgen deprivation therapy (ADT) (n=-9)
-
metastatic, hormone-sensitive prostate cancer
GETUG-AFU 15, 2013 NCT00104715
docetaxel plus ADT (n=-9) vs. androgen deprivation therapy (ADT) (n=-9)
randomized controlled trial
docetaxel and androgen-deprivation therapy (ADT)
androgen-deprivation therapy (ADT) alone
ADT (orchiectomy or luteinising hormone-releasing hormone agonists, alone or combined with non-steroidal antiandrogens) alone
metastatic, hormone-sensitive prostate cancer